Antibiotic resistant bacteria survive treatment by doubling while shrinking
preprint
OA: gold
CC-BY-4.0
Abstract
Many antibiotics that are used in healthcare, farming and aquaculture end up in environments with different spatial structures that might promote heterogeneity in the emergence of antibiotic resistance. However, experimental evolution of microbes at sub-inhibitory concentrations of antibiotics has been mainly carried out at the population level which does not allow capturing heterogeneity within bacterial populations. Here we investigate and compare the emergence of resistance to ciprofloxacin in Escherichia coli in well mixed and structured environments using experimental evolution, genomics and microfluidics-based time-lapse microscopy. We discover that resistance to ciprofloxacin and cross-resistance to other antibiotics is stronger in the well-mixed environment due to the emergence of target mutations, whereas efflux regulator mutations emerge in the structured environment. The latter mutants also harbour sub-populations of persisters that survive high concentrations of ciprofloxacin that inhibit bacterial growth at the population level. In contrast, genetically resistant bacteria that display target mutations also survive high concentrations of ciprofloxacin that inhibit their growth via population-level antibiotic tolerance. These resistant and tolerant bacteria keep doubling while shrinking in size in the presence of ciprofloxacin and regain their original size after antibiotic removal, which constitutes a newly discovered phenotypic response. This new knowledge sheds light on the diversity of strategies employed by bacteria to survive antibiotics and poses a stepping stone for understanding the link between mutations at the population level and phenotypic single-cell responses.
My notes (saved in your browser only)
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (4)
- Membrane permeability selection drove the stereochemistry of life 2024
- Heterogeneous efflux pump expression underpins phenotypic resistance to antimicrobial peptides 2024
- Systematic mapping of antibiotic cross-resistance and collateral sensitivity with chemical genetics 2024
- Phage-induced efflux down-regulation boosts antibiotic efficacy 2023
References (79)
- Heterogeneous efflux pump expression underpins phenotypic resistance to antimicrobial peptides via crossref
- Membrane permeability selection drove the stereochemistry of life via crossref
- Phage-induced efflux down-regulation boosts antibiotic efficacy via crossref
- Systematic mapping of antibiotic cross-resistance and collateral sensitivity with chemical genetics via crossref
- doi:10.1186/s12915-017-0465-4 via crossref
- doi:10.1038/s41579-020-00443-1 via crossref
- doi:10.1038/s41467-019-12426-9 via crossref
- doi:10.1179/1973947815y.0000000038 via crossref
- doi:10.1126/science.aag0822 via crossref
- doi:10.1038/nmicrobiol.2016.20 via crossref
- doi:10.1371/journal.pgen.1003144 via crossref
- doi:10.1117/12.2507329 via crossref
- doi:10.1073/pnas.1420702111 via crossref
- doi:10.1073/pnas.2216216120 via crossref
- doi:10.1038/nrmicro.2016.34 via crossref
- doi:10.1098/rspb.2003.2556 via crossref
- doi:10.1021/acsinfecdis.0c00681 via crossref
- doi:10.1038/s41598-022-07973-z via crossref
- doi:10.1038/srep32824 via crossref
- doi:10.1039/d0lc00242a via crossref
- doi:10.1016/j.resmic.2005.02.004 via crossref
- doi:10.1038/nature05685 via crossref
- doi:10.1111/bcp.15042 via crossref
- doi:10.1038/s41598-020-65602-z via crossref
- doi:10.1126/science.6243420 via crossref
- doi:10.1128/aac.00013-21 via crossref
- doi:10.1042/bst20210894 via crossref
- doi:10.2147/idr.s234610 via crossref
- doi:10.1063/1.4865552 via crossref
- doi:10.1126/science.1198767 via crossref
- doi:10.1021/acsinfecdis.1c00154 via crossref
- doi:10.1126/sciadv.aax2950 via crossref
- doi:10.1021/acsinfecdis.0c00001 via crossref
- doi:10.1371/journal.ppat.1002357 via crossref
- doi:10.1111/evo.13833 via crossref
- doi:10.1111/nyas.12830 via crossref
- doi:10.1093/nar/gky895 via crossref
- doi:10.1093/molbev/msx052 via crossref
- doi:10.1128/aac.44.3.710-712.2000 via crossref
- doi:10.1016/j.mib.2014.02.006 via crossref
- doi:10.1128/aac.00493-13 via crossref
- doi:10.3947/ic.2014.46.4.226 via crossref
- doi:10.3390/antibiotics10121506 via crossref
- doi:10.1098/rstb.2018.0442 via crossref
- doi:10.1371/journal.pbio.3001958 via crossref
- doi:10.7554/elife.74062 via crossref
- doi:10.1038/msb.2013.57 via crossref
- doi:10.1016/j.ijantimicag.2004.11.012 via crossref
- doi:10.1093/infdis/jiw282 via crossref
- doi:10.1128/aac.50.3.975-983.2006 via crossref
- doi:10.1016/j.celrep.2016.09.001 via crossref
- doi:10.1016/j.mib.2020.06.009 via crossref
- doi:10.1002/ppul.20671 via crossref
- doi:10.1016/s0140-6736(21)02724-0 via crossref
- doi:10.1128/jb.187.18.6265-6272.2005 via crossref
- doi:10.1093/molbev/msu191 via crossref
- doi:10.1039/c1lc20399a via crossref
- doi:10.1016/j.tim.2015.02.009 via crossref
- doi:10.1038/nrg3351 via crossref
- doi:10.1016/j.immuni.2021.10.012 via crossref
- doi:10.1016/j.molcel.2016.03.035 via crossref
- doi:10.1016/j.tim.2019.02.003 via crossref
- doi:10.3389/fmicb.2018.01739 via crossref
- doi:10.1038/s41598-019-46567-0 via crossref
- doi:10.3389/fmicb.2020.00665 via crossref
- doi:10.1038/s42003-020-01176-w via crossref
- doi:10.4187/respcare.06697 via crossref
- doi:10.1038/s41579-018-0147-4 via crossref
- doi:10.1007/s00203-021-02585-z via crossref
- doi:10.1016/j.cub.2010.04.045 via crossref
- doi:10.1371/journal.ppat.1008437 via crossref
- doi:10.1038/s42003-019-0672-3 via crossref
- doi:10.1128/mbio.02095-19 via crossref
- doi:10.1038/s41396-019-0344-9 via crossref
- doi:10.1038/nrmicro3270 via crossref
- doi:10.1038/s41467-018-04059-1 via crossref
- doi:10.1371/journal.pbio.3001406 via crossref
- doi:10.1038/s43705-023-00319-4 via crossref
- doi:10.1038/s41579-019-0196-3 via crossref
Source provenance
- crossref
- last seen: 2026-06-06T01:00:28.466777+00:00
- europepmc
- last seen: 2026-05-20T01:45:00.602351+00:00
- unpaywall
- last seen: 2026-05-21T02:00:01.467718+00:00
License: CC-BY-4.0